GW Pharmaceuticals PLC closed at $127.05 in the latest trading session, marking a +0.63% move from the prior day. The stock outpaced the S&P 500's daily loss of 3.24%. Elsewhere, the Dow lost 3.1%, while the tech-heavy Nasdaq lost 3.8%.
Heading into today, shares of the company had lost 13.36% over the past month, lagging the Medical sector's gain of 4.97% and the S&P 500's gain of 2.73% in that time.
Wall Street will be looking for positivity from GWPH as it approaches its next earnings report date. This is expected to be February 4, 2019. The company is expected to report EPS of -$2.67, down 9.88% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $12.47 million, up 61.27% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$7.93 per share and revenue of $115.34 million, which would represent changes of +24.91% and +580.26%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for GWPH. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 17.02% lower. GWPH is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 143, putting it in the bottom 44% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Image: Bigstock
GW Pharmaceuticals PLC (GWPH) Gains As Market Dips: What You Should Know
GW Pharmaceuticals PLC closed at $127.05 in the latest trading session, marking a +0.63% move from the prior day. The stock outpaced the S&P 500's daily loss of 3.24%. Elsewhere, the Dow lost 3.1%, while the tech-heavy Nasdaq lost 3.8%.
Heading into today, shares of the company had lost 13.36% over the past month, lagging the Medical sector's gain of 4.97% and the S&P 500's gain of 2.73% in that time.
Wall Street will be looking for positivity from GWPH as it approaches its next earnings report date. This is expected to be February 4, 2019. The company is expected to report EPS of -$2.67, down 9.88% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $12.47 million, up 61.27% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$7.93 per share and revenue of $115.34 million, which would represent changes of +24.91% and +580.26%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for GWPH. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 17.02% lower. GWPH is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 143, putting it in the bottom 44% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.